TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05821192
Drug: PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg on Days 2 by IV infusion once every 3 weeks
Study: NCT06558838
Drug: acyclovir-penciclovir cream
Normalized name: Penciclovir
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will treat their cold sore with active study drug based upon their randomization
Study: NCT06558838
Drug: Abreva
Normalized name: Abreva
DrugBank: Docosanol (DB00632)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will treat their cold sore with Abreva based upon their randomization
Study: NCT06056583
Drug: Cimetidine 200 MG
Normalized name: cimetidine 200 MG
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine will serve as the probe drug
Study: NCT04303559
Drug: Emicizumab Injection [Hemlibra]
Normalized name: emicizumab Injection [Hemlibra]
DrugBank: Emicizumab (DB13923)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is a bispecific monoclonal antibody FVIII mimic.
Study: NCT06059989
Drug: Infliximab subcutaneous
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mono and combination therapy group
Study: NCT04538820
Drug: Dexamethasone 4 mg IV-control
Normalized name: dexamethasone 4 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to normal weight patients.
Study: NCT04538820
Drug: Dexamethasone 4 mg IV
Normalized name: dexamethasone 4 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
Study: NCT04538820
Drug: Dexamethasone 8 mg IV
Normalized name: dexamethasone 8 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone 8 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
Study: NCT06358066
Drug: self assembling peptide p11-4 with fluoride
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-assembling peptide (P11-4) fluoride plus will be applied according to the manufacturer's instructions by pushing the two cylinders together and will left for 5 min till the tooth surface appears dry to insure its diffusion~The remineralizing process of the early enamel carious lesions will be assessed quantitatively using the laser fluorescence DIAGNOdent measuring and assessed qualitatively using ICDAS II scoring system at baseline 1, 3, 6 months post-treatment
Study: NCT06358066
Drug: 5% sodium fluoride varnish
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoride varnish will be applied under manufacturer instructions by applying thin layer of varnish with a brush in strokes The remineralizing process of the early enamel carious lesions will be assessed quantitatively using the laser fluorescence DIAGNOdent measuring and assessed qualitatively using ICDAS II scoring system at baseline 1, 3, 6 months post-treatment
Study: NCT04770935
Drug: efanesoctocog alfa (BIVV001)
Normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for injection Route of administration: intravenous injection
Study: NCT05635604
Drug: Eptinezumab
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptinezumab or ALD403 is a humanized anti-calcitonin gene-related peptide IgG1 monoclonal antibody that binds to calcitonin gene-related peptide (CGRP). It selectively binds human CGRP ligand to prevent activation of the CGRP receptor and blocks its binding to the receptor for the prevention of migraine.
Study: NCT05635604
Drug: PACAP-38
DrugBank: PACAP38 (DB17073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PACAP-38 is a naturally occurring peptide diffusely expressed throughout the body. The Danish Headache Center has used infusion of PACAP-38 for several years and the first time in 2007 where infusion of PACAP-38 triggered headaches and migraines in migraine patients.
Study: NCT06725810
Drug: enadustat
Normalized name: Enarodustat
DrugBank: Enarodustat (DB14985)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Patients are administered with enarodustat with dosage adjusted according to hemoglobin levels to achieve and maintain hemoglobin target over 96 weeks.
Study: NCT06727201
Drug: Ondansetron (Zofran)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron will be given intravenously in a dose of 0.1mg/kg 10 minutes before spinal anaesthesia as single shot.
Study: NCT06727201
Drug: Saline (NaCl 0,9 %) (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: normal saline infusion will be given intravenously 10 minutes before spinal anaesthesia
Study: NCT06726278
Drug: Misoprostol 400mcg Tab
Normalized name: Misoprostol Tablets
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 400 µg is a synthetic prostaglandin E1 analog used in this clinical trial to evaluate its effects in inducing uterine contractions or labor. This dosage form is typically administered orally, and its primary mechanism involves the softening and dilation of the cervix, making it a common choice in obstetric practices for labor induction. The study will evaluate its efficacy and safety profile when compared to the placebo group. Misoprostol is administered in a single dose of 400 µg, and participants will be monitored for any adverse reactions or labor-related outcomes.
Study: NCT06725758
Drug: ODM-212
Normalized name: ODM-203
DrugBank: ODM-203 (DB16843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODM-212 5mg and/or 40mg tablets
Study: NCT05312268
Drug: Rasburicase
Normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rasburicase 1.5 mg/day for 3 consecutive days at scheduled times.
Study: NCT06202599
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients with pulmonary metastasis only, we mostly gave them fruquintinib with 7 mg in adults and 3-5 mg in children (\<10 years) orally per day (5 days on and 2 days off). If patients were extrapulmonary metastasis, we usually used combinations with metronomic chemotherapy (2/3 or 3/5 or even 1/2 of the usual dose) or immunotherapy.
Study: NCT05315336
Drug: L-DEP and PD-1 antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; PD-1 antibody injection 200mg day 5; L-asparaginases 6000iu/m2 day2, day4. This regimen was repeated after 2 weeks.
Study: NCT06225999
Drug: Irinotecan liposome injection (S095013)
Normalized name: Irinotecan liposome injection
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan liposome injection (S095013) will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
Study: NCT06225999
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
Study: NCT06231979
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 μg/kg Dexmedetomidine per side in erector spinae block
Study: NCT06231979
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18 mL of bupivacaine 0.25 % per side in erector spinae block
Study: NCT06225999
Drug: 5- FU (5-Fluorouracil)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
Study: NCT06345833
Drug: 1%Tranexamic acid with standard local
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1% TXA mixed with standard local consisting 1/4% lidocaine with 1:100,000 epinephrine with saline as the control.
Study: NCT05861557
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg, Q3W，I.V., D1, 2 cycles (1cycle of toripalimab before and after the SBRT radiotherapy, respectively), followed by the maintenance of toripalimab for 6 months after the surgery.
Study: NCT06047860
Drug: Granulocyte-macrophage colony-stimulating factor subcutaneous injection
Normalized name: Recombinant human granulocyte-macrophage colony stimulating factor
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
Study: NCT06047860
Drug: Interleukin 2 subcutaneous injection
Normalized name: Interleukin 11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
Study: NCT06047860
Drug: Endostatin
Normalized name: Endostatin
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human vascular endothelial inhibitor (Endo) 210 mg CIV72h was started on the first day of treatment, every 21 days for a minimum of ≥ 2 cycles of this combination therapy.
Study: NCT05429398
Drug: Linperlisib Tablet
Normalized name: Linperlisib
DrugBank: Linperlisib (DB17235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Linperlisib Tablet Oral administration, once a day, for 21 consecutive days as a treatment cycle;~2. Camrelizumab for Injection 200 mg intravenously every 3 weeks. Camrelizumab should be administered prior to Linperlisib.
Study: NCT04949828
Drug: CREON
Normalized name: Creon
DrugBank: Pancrelipase amylase (DB11065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsules
Study: NCT04898322
Drug: SY-005
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
Study: NCT04898322
Drug: SY-005
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
Study: NCT04898322
Drug: SY-005
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
Study: NCT04730856
Drug: Tinzaparin
Normalized name: Tinzaparin
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: day subcutaneously • Follow-up phase 1 (Day 15 to day 30): The information is obtained at discharge and on day +14, + 28 on 30 days. The latter information is obtained from patients, from medical records or by telephone contact at the patient's home.~• Follow-up phase 2 (At 3 months: Information is obtained from patients, medical records, or by telephone contact at the patient's home.
Study: NCT05319886
Drug: Anlotinib and Penpulimab
Normalized name: cytarabine and daunorubicin
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 12mg, po, qd, with 2 weeks off for 1 week. Penpulimab 200mg, ivgtt, q3w. Efficacy was evaluated every 2 cycles. Efficacy evaluation was performed every 2 cycles during the follow-up study. Patients with disease control (CR+PR+SD) and tolerable adverse reactions continued to take the drug until the investigator considered that the patient was not suitable to continue the drug or the efficacy was evaluated as PD. Safety evaluations were performed concurrently with the dosing period. No other antitumor therapy can be administered until PD.
Study: NCT05234190
Drug: QEL-001
Normalized name: Qelbree
DrugBank: Viloxazine (DB09185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QEL-001 is an autologous therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against HLA-A2. Treatment will be given via an IV infusion.
Study: NCT05629364
Drug: KIO-101
Normalized name: KIO-301
DrugBank: KIO-301 (DB18465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized, Controlled
Study: NCT06465433
Drug: Tafasitamab
Normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.
Study: NCT06288152
Drug: Sodium Thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.15 mL administered
Study: NCT00508963
Drug: sodium stibogluconate (Pentostam)
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg IV every day for 20 or 28 days
Study: NCT06022536
Drug: SSS40
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects injected with SSS40
Study: NCT05337345
Drug: Cendakimab
Normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified Dose on Specified Days
Study: NCT06474078
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage/Frequency: 5mg - 10mg, oral, twice daily
Study: NCT05545072
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dupilumab will be administered subcutaneously at a dose of 300 milligrams (mg) in a 2 milliliter (mL) solution every 2 weeks until the end of treatment (EOT) at Week 52. Participants will receive a total of 26 doses.
Study: NCT06527781
Drug: PD5K3
Normalized name: Phendimetrazine
DrugBank: Phendimetrazine (DB01579)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six dose levels will be evaluated. intravenous injection
Study: NCT06527781
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six dose levels will be evaluated. intramuscular injection
Study: NCT04854551
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone is an opioid antagonist with primary action at the mu opioid receptor.
Study: NCT04270175
Drug: Daratumumab SC
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given as 1800mg via injection
Study: NCT04270175
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given as 4mg oral capsule
Study: NCT04270175
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given as 20mg or 40 mg IV and 20mg or 40mg oral tablet.
Study: NCT06145854
Drug: Cabotegravir Injection [Apretude]
Normalized name: cabotegravir Injection [Apretude]
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apretude for PrEP
Study: NCT05279092
Drug: Bupivacaine-Liposomal Bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an iPACK block
Study: NCT05279092
Drug: Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.
Study: NCT05903027
Drug: Rimegepant 75 MG Disintegrating Oral Tablet
Normalized name: rimegepant 75 MG Disintegrating Oral Tablet
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks
Study: NCT04523857
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)
Study: NCT04523857
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral autophagy inhibitor to target bone marrow disseminated tumor cells (DTCs)
Study: NCT04218409
Drug: OxyCODONE 5 mg Oral Tablet
Normalized name: oxyCODONE 5 mg oral tablet
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral oxycodone 5 mg orally
Study: NCT04218409
Drug: Oxytocin nasal spray
Normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin administration (48 IU)
Study: NCT04218409
Drug: OxyCODONE 2.5 mg Oral Tablet
Normalized name: ASA 325 MG / Oxycodone 2.5 MG Oral Tablet
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral oxycodone 2.5 mg orally
Study: NCT06540963
Drug: Tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT06540963
Drug: Naxitamab
Normalized name: Naxitamab
DrugBank: Naxitamab (DB15965)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT05236608
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered together with ADG106 via intravenous infusion.
Study: NCT04713163
Drug: covid19 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine
Study: NCT06097663
Drug: MAS825
Normalized name: MAS825
DrugBank: MAS825 (DB16452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active MAS825 single dose
Study: NCT06097663
Drug: MAS825 Placebo
DrugBank: MAS825 (DB16452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAS825 placebo single dose
Study: NCT06097663
Drug: DFV890
Normalized name: DFV890
DrugBank: DFV890 (DB16461)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet of DFV890 active once daily
Study: NCT06097663
Drug: DFV890 placebo
DrugBank: DFV890 (DB16461)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet of DFV890 placebo once daily
Study: NCT05903963
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam infusion by 0.03-0.3mg/kg in increments of 1-2.5mg followed by Maintenance dose: 0.03-0.2mg/kg/hour for midazolam.
Study: NCT05903963
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine infusion 1 µg/kg dexmedetomidine for 10 minutes followed by a continuous IV infusion at 0.2-0.3 µg/kg/hour .
Study: NCT06492889
Drug: Levonorgestrel
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants in the levonorgestrel plus mifepristone group will receive one tablet of 1.5 mg levonorgestrel
Study: NCT06492889
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in both groups will receive one tablet of 200 mg mifepristone
Study: NCT04922658
Drug: Surufatinib
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib,300mg, qd, po, 21 days for a cycle; continuous administration until PD, death or intolerable toxicity.
Study: NCT04922658
Drug: Surufatinib Plus Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surufatinib, 250mg, qd, po; Plus Vinorelbine, 20 mg, every 2 days; 21days for a cycle; continuous administration until PD, death or intolerable toxicity.
Study: NCT05369793
Drug: Alpha lipoic acid
Normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months.
Study: NCT05079061
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual misoprostol 600 micrograms in addition routine uterotonics at third stage of labour
Study: NCT05369793
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administration of 500 mcg plus vildagliptin/metformin combination(50/1000mg) orally once daily for 3 months.
Study: NCT05783492
Drug: Intranasal ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/kg single dose in 0.5 mL sprays in each nare separated by 60 seconds
Study: NCT05493124
Drug: Active comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drugs that may have therapeutic effects
Study: NCT04498468
Drug: Sustained Release Dexamethasone, 0.4 mg
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone 0.4mg lacrimal insert
Study: NCT05975645
Drug: Penpulimab injection
Normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penpulimab is an inhibitor of programmed cell death 1 (PD-1).
Study: NCT05975645
Drug: Anlotinib Hydrochloride Capsules
Normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
Study: NCT05946603
Drug: Administration of IS-002
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of IS-002 approximately 24 hours prior to surgery
Study: NCT05156450
Drug: TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone
Normalized name: ABIRATERONE ACETATE
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with TQB3616 in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer.
Study: NCT05451017
Drug: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition
Normalized name: 17-hydroxy-19-nor-17-α-pregn-4-en-20-yn-3-one
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single dose of 1 mg AEF0117 in fed condition